About Cellumen
Cellumen is a company based in Pittsburgh (United States) founded in 2004 was acquired by Apredica in August 2010.. Cellumen has raised $11.43 million across 11 funding rounds from investors including Safeguard Scientifics, Novitas Capital and Apredica. Cellumen offers products and services including Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products. Cellumen operates in a competitive market with competitors including Aganitha, PointCross, IOTA Pharma, Emergentec and Growdea Technologies, among others.
- Headquarter Pittsburgh, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$11.43 M (USD)
in 11 rounds
-
Latest Funding Round
$248.45 K (USD), Series B
Mar 03, 2010
-
Investors
Safeguard Scientifics
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Apredica
(Aug 05, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellumen
Cellumen offers a comprehensive portfolio of products and services, including Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Kits for detecting biomolecules in biological samples
Proteins used for identifying specific antigens in research
Kits for enzyme-linked assays in protein detection
Kit for quantifying proteins in serum and tissues
Products for DNA analysis and templates in experiments
Funding Insights of Cellumen
Cellumen has successfully raised a total of $11.43M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $248.45 thousand completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series B — $248,453
-
First Round
First Round
(20 Jun 2004)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2010 | Amount | Series B - Cellumen | Valuation |
investors |
|
| Nov, 2009 | Amount | Series B - Cellumen | Valuation |
investors |
|
| May, 2009 | Amount | Series B - Cellumen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cellumen
Cellumen has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Safeguard Scientifics, Novitas Capital and Apredica. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in early and growth stage companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Content on research ethics is shared by Apredica.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cellumen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cellumen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellumen Comparisons
Competitors of Cellumen
Cellumen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aganitha, PointCross, IOTA Pharma, Emergentec and Growdea Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of AI-powered drug discovery and development solutions
|
|
| domain | founded_year | HQ Location |
Big data platform & desktop software for preclinical & clinical research & regulatory applications
|
|
| domain | founded_year | HQ Location |
Offers fragment-based drug discovery products and services.
|
|
| domain | founded_year | HQ Location |
Computational solutions and consulting for better decision making in biomarker, target and drug development.
|
|
| domain | founded_year | HQ Location |
Offers AI and machine learning for in-silico drug discovery and bioinformatics services.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Cellumen
When was Cellumen founded?
Cellumen was founded in 2004.
Where is Cellumen located?
Cellumen is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Is Cellumen a funded company?
Cellumen is a funded company, having raised a total of $11.43M across 11 funding rounds to date. The company's 1st funding round was a Series B of $621.76K, raised on Jun 20, 2004.
What does Cellumen do?
Cellumen, acquired by Cyprotex (formerly Apredica) in 2010, was a company offering proprietary cellular systems biology-based solutions for in vitro discovery and toxicology testing of drug candidates. The company had IP w.r.t reagents and multiplexed assays using the High Content Screening platform. The company offered drug discovery and toxicology screening services and was working with immortalised HepG2 human cell lines, primary rat hepatocytes and cardiac cell lines. At the core of Cellumens expertise was its CellCiphr toxicity risk assessment technology. The company had developed CellCiphr profiles by screening a library of compounds and characterising them. These were used to identify and screen potentially toxic compounds at a much earlier stage in the drug discovery process. The company claimed that it could demonstrate savings of up to USD 91Myear for any big pharma company by applying their CellCiphr filter at the start of the hit-to-lead phase.
Who are the top competitors of Cellumen?
Cellumen's top competitors include Aganitha, PointCross and Emergentec.
What products or services does Cellumen offer?
Cellumen offers Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products.
Who are Cellumen's investors?
Cellumen has 3 investors. Key investors include Safeguard Scientifics, Novitas Capital, and Apredica.